Joerg Schwarz, M.S., is the Senior Director of Healthcare Interoperability at Infor. He believes providers will harness the power of generative AI in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Joerg Schwarz, M.S., had to say:
"Healthcare executives are cautious about using generative artificial intelligence (AI) for clinical content, and we can expect this apprehension to extend well into 2024, primarily because of the overabundance of unstructured data. Healthcare chief information officers and chief technology officers will begin implementing a data analytics platform strategy combining data from different sources (Internet of Things, electronic health records, enterprise resource planning) in 2024, with hopes of using this platform to feed the many AI algorithms that promise improved operational and clinical outcomes.
Although healthcare providers recognize the potential of generative AI, 2024 will be the year when organizations come together and work to train algorithms for reliable results, in parallel with good governance models.”
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More